1. [Treatment of intrastent restenosis by drug eluting stents: experience from one cardiology centre]
- Author
-
Ma, Majdoub, Sauguet A, Tchetche D, Ducrocq G, Benamer H, Himbert D, Aubry P, Lj, Feldman, Philippe Gabriel STEG, and Jm, Juliard
- Subjects
Adult ,Aged, 80 and over ,Male ,Sirolimus ,Ticlopidine ,Aspirin ,Paclitaxel ,Surface Properties ,Coronary Thrombosis ,Myocardial Infarction ,Myocardial Ischemia ,Equipment Design ,Middle Aged ,Coronary Angiography ,Angina Pectoris ,Clopidogrel ,Coronary Restenosis ,Treatment Outcome ,Humans ,Female ,Stents ,Prospective Studies ,Platelet Aggregation Inhibitors ,Aged ,Follow-Up Studies - Abstract
Many interventional treatments have been proposed for intrastent stenosis, in particular by drug-eluting stents, with encouraging results. The aim of this study was to assess the clinical outcome of patients with restenosis of an ordinary uncovered stent treated by a drug eluting stent in a prospective series. The register included 43 patients (50 intrastent restenoses) treated by a drug eluting stent (Cypher or Taxus). The restenosis lesion was focal in 32% of cases with an average length of 14.8 +/- 8 mm and diameter inferior to 2.5 mm in 48% of cases. A Cypher stent was implanted in 44% of cases and a Taxus stent in 56% of cases. After an average follow-up of 6.7 +/- 1.3 months, the major adverse cardiac event rate was 9.3%. It included one transmural infarct in a patient, due to stent thrombosis, and symptomatic restenoses in 3 patients (clinical restenosis rate: 7%). An angiographic control was performed in 15 patients (35%) identifying focal restenosis at the exit of the stent in the 3 symptomatic patients. As in previously reported studies, these results show that with well conducted platelet antiaggregant therapy, the treatment of intrastent restenosis with a drug eluting stent is effective with a low rate of adverse cardiovascular events which compares favourably with previously proposed techniques of management.